Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

Events Timeline

(ET)

2026-02-26

08:00:00

Zai Lab Reports Q4 Revenue of $127.6M

2026-01-06 (ET)

2026-01-06

07:40:00

Zai Lab Receives Approval for Augtryo to Treat Adult Solid Tumors

2025-12-24 (ET)

2025-12-24

10:10:00

Zai Lab Shares Rise 7.4% to $18.77

2025-12-23 (ET)

2025-12-23

09:10:00

U.S. Economic Growth Exceeds Expectations, Stock Futures Edge Lower

2025-12-23

07:50:00

Zai Lab Receives China's Approval for Cobenfy to Treat Schizophrenia in Adults

News

9.5

02-26seekingalpha

Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress

9.5

02-25seekingalpha

Zai Lab Scheduled to Announce Q4 Earnings on February 26

4.0

02-20moomoo

ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53

8.5

02-05PRnewswire

Oncolytics Biotech Receives FDA Fast Track Designation

8.5

02-05Newsfilter

FDA Accelerates Oncology Drug Approvals, Boosting Market Potential

6.5

02-04seekingalpha

ClearBridge International Growth Strategy Underperforms in Q4 2025

5 Analyst Rating

Wall Street analysts forecast ZLAB stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

Current: 0.000

Low

25.70

Averages

47.93

High

74.00

Cantor Fitzgerald

Overweight

downgrade

$55 -> $37

AI Analysis

2026-02-27

New

Reason

Cantor Fitzgerald

Price Target

$55 -> $37

AI Analysis

2026-02-27

New

downgrade

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Zai Lab to $37 from $55 and keeps an Overweight rating on the shares. Zai Lab reported Q4 and full-year revenues of $127.6M and $460.2M, respectively, in line with consensus, though Vyvgart sales were slightly weaker than expected, the analyst tells investors in a research note. Management indicated that 2026 top-line growth is likely to be modest, with volume gains offset by pricing pressures and competition in China, the firm says.

Citi

Yigal Nochomovitz

Buy

downgrade

$53 -> $47

2026-02-27

New

Reason

Citi

Yigal Nochomovitz

Price Target

$53 -> $47

2026-02-27

New

downgrade

Buy

Reason

Citi analyst Yigal Nochomovitz lowered the firm's price target on Zai Lab to $47 from $53 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZLAB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is -18.08, compared to its 5-year average forward P/E of -18.04. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.04

Current PE

-18.08

Overvalued PE

2.84

Undervalued PE

-38.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.28

Current EV/EBITDA

-27.61

Overvalued EV/EBITDA

-0.10

Undervalued EV/EBITDA

-28.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.42

Current PS

3.52

Overvalued PS

38.47

Undervalued PS

-3.62

Financials

AI Analysis

Annual

Quarterly

Whales Holding ZLAB

Frazier Life Sciences Management, LP

Rock Springs Capital Management LP

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 17.72 USD — it has decreased -3.8

What is Zai Lab Ltd (ZLAB)'s business?

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 127.60M USD, increased 16.99

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -37.50

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1784 emplpoyees as of March 04 2026.

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 1.96B USD.

ZLAB Overview

ZLAB Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding ZLAB

Trading Trends

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

What is Zai Lab Ltd (ZLAB)'s business?

What is the price predicton of ZLAB Stock?

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

How many employees does Zai Lab Ltd (ZLAB). have?

What is Zai Lab Ltd (ZLAB) market cap?